Evidence map›Paper›PMID 36735263›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Epicardial vs. transvenous implantable cardioverter defibrillators in children.

Pierre Antoine Le Bos, Margaux Pontailler, Alice Maltret, Diala Kraiche, Regis Gaudin, Claudio Barbanti, Eloi Marijon, Olivier Raisky, Damien Bonnet, Victor Waldmann

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05349162 (Epicardial Versus Transvenous Implantable Cardioverter Defibrillators in Children), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05349162 completednot on this map

Epicardial Versus Transvenous Implantable Cardioverter Defibrillators in Children

TypeobservationalSponsorParis Cardiovascular Research Center (Inserm U970)Ran2003 to 2022Enrolled131ConditionsImplantable Cardioverter Defibrillator Complications, Implantable Defibrillator UserArmsImplantable cardioverter defibrillator use
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Outcomes for patients implanted with a cardioverter-defibrillator at <19 years of age: a Swedish national study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  2. The SIDECAR 2.0 (S-ICD registry in European paediatric and young adult patients with congenital heart defects 2.0): an analysis of European S-ICD clinical practice and its evolution in paediatric patients.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Observational
  3. Review
  4. Article
  5. Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pierre Antoine Le BosM3C-Necker, Hôpital Universitaire Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.ORCID 0000-0003-1033-9828
Margaux PontaillerDepartment of Pediatric Cardiac Surgery, Necker Hospital, 149 rue de Sèvres, 75015 Paris, France.ORCID 0000-0001-9375-2444
Alice MaltretM3C-Necker, Hôpital Universitaire Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.ORCID 0000-0001-9934-6746
Diala KraicheM3C-Necker, Hôpital Universitaire Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.ORCID 0000-0002-3437-9333
Regis GaudinDepartment of Pediatric Cardiac Surgery, Necker Hospital, 149 rue de Sèvres, 75015 Paris, France.
Claudio BarbantiPediatric Cardiac Anesthesia and Cardiopulmonary Unit, Necker Hospital, 149 rue de Sèvres, 75015 Paris, France.
Eloi MarijonUniversité de Paris Cité, INSERM, Paris Cardiovascular Research Centre, 56 rue Leblanc, 75015 Paris, France.ORCID 0000-0001-7227-3428
Olivier RaiskyDepartment of Pediatric Cardiac Surgery, Necker Hospital, 149 rue de Sèvres, 75015 Paris, France.
Damien BonnetM3C-Necker, Hôpital Universitaire Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.
Victor WaldmannM3C-Necker, Hôpital Universitaire Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.ORCID 0000-0001-8057-1900
Hôpital Necker-Enfants Malades · FRInserm · FR

Funding

Fédération Française de CardiologieFrench Institute of Health and Medical ResearchSociété Française de Cardiologie
6 · The paper itself

Abstract

aimsThe implantable cardioverter defibrillator (ICD) has been increasingly used in children. Both epicardial and transvenous approaches are used, with controversy regarding the best option with no specific recommendations. We aimed to compare outcomes associated with epicardial vs. transvenous ICDs in children. METHODS AND

resultsData were analysed from a retrospective study including all patients <18-year-old implanted with an ICD in a tertiary centre from 2003 to 2021. Outcomes were compared between epicardial and transvenous ICDs. A total of 122 children with an ICD (mean age 11.5 ± 3.8 years, 57.4% males) were enrolled, with 84 (64.1%) epicardial ICDs and 38 (29.0%) transvenous ICDs. Early (<30 days) ICD-related complications were reported in 17 (20.2%) patients with an epicardial ICD vs. 0 (0.0%) with a transvenous ICD (P = 0.002). Over a mean follow-up of 4.8 ± 4.0 years, 25 (29.8%) patients with an epicardial ICD and 9 (23.7%) patients with a transvenous ICD experienced at least one late ICD-related complication [hazard ratio (HR) 1.8, 95% confidence interval (CI) 0.8-4.0]. Implantable cardioverter defibrillator lead dysfunction occurred in 19 (22.6%) patients with an epicardial ICD vs. 3 (7.9%) with a transvenous ICD (HR 5.7, 95% CI 1.3-24.5) and was associated with a higher incidence of ICD-related reintervention (HR 3.0, 95% CI 1.3-7.0). After considering potential confounders, especially age and weight at implantation, this association was no longer significant (P = 0.112). The freedom from ICD lead dysfunction was greater in patients with pleural coils than in those with epicardial coils (HR 0.38, 95% CI 0.15-0.96).

conclusionIn children, after a consideration of patient characteristics at implantation, the burden of complications and ICD lead dysfunction appears to be similar in patients with epicardial and transvenous devices. Pleural coils seem to be associated with better outcomes than epicardial coils in this population. CLINICAL

trial registrationNCT05349162.

Indexed as

Defibrillators, ImplantableAdolescentArrhythmias, CardiacChildDeath, Sudden, CardiacFemaleHumansMaleRetrospective StudiesTreatment OutcomeCongenital heart diseaseImplantable cardioverter defibrillatorPaediatricSudden deathVentricular arrhythmia

Identifiers

PMID36735263
PMCPMC10062323
OpenAlexW4319063619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.